News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Pharma 50 Trends: Past, Present, and Future

June 9, 2014
By William Looney
Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive-06-01-2014
Volume 0
Issue 0

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

THIS MONTH'S TOP FEATURE is our annual review of who tops the league in industry sales—a standard benchmark of success that has remained surprisingly static since we began ranking the 50 largest players back in our April 2000 issue. Over these 14 years, just three companies—Merck (in 2000), Pfizer (from 2001 to 2013), and Novartis (this year) —have snagged the No. 1 position. Much of the real action has taken place well below the top, particularly among those middle-ranked companies which have achieved the scale to compete globally but where size has not yet proved a distraction against the bottom line.

William Looney

As befits a publication with deep roots, Pharm Exec's Top 50 has been around enough to reveal the importance of leading with a unique business model and then sticking with it, for the long-term. Two obscure entries on that first April 2000 list were Genentech (at No. 42) and Teva (at 43). By 2007, at the halfway point in the history of our survey, both companies had risen to a position in the top 20, paced by their achievements in securing dominant positions in the innovative cancer and generic segments, respectively. Teva—now twelfth in this year's list—will likely strike the top 10 next year, while the absorption of Genentech by Roche in 2009 has had much to do with its parent's own rapid rise from eighth place that year, to third.

What we are seeing now is a similarly decisive distinction favoring companies that made an early commitment to focus on specialty biologics for hard-to-treat conditions affecting small target populations. It's only a matter of time before these outliers—like Celgene (at 26 this year), Biogen Idec (27) and Shire (32)—breach that top 20 barrier, too.

Still, it is pertinent to ask whether such rankings remain the best way to document true leadership in the industry. Pharm Exec is a media enterprise and like everyone we face pressures to communicate in short, easy information bits; lists do serve a purpose in distilling complexity into a stimulating, commemorative tonic. But their shelf life is brief. In fact, the strategy dialogue within biopharmaceuticals today has shifted from celebrating bigness and scale—organizational attributes deemed critical to finding that "blue ocean space" beyond the reach of competitors—to embracing the concept of "fleetness," where the ability to make rapid, turn-on-a-dime decisions is essential to keeping pace with a business environment in perpetual motion.

According to Columbia Business School Professor Rita McGrath, "If you think of competitive advantage today as something temporary or transient, you'll organize your company in a very different way. And you will re-do it often." In other words, in this world, size can be a drag. Foresight is a lot harder when you are at the top, looking down, not out. And few executives want to confront the trade-offs from being aware that the biggest threats to the business might be in adjacent industries and sectors: that is, beyond the Pharma 50, not within it.

The dismembering of competitive advantage is so dramatic that the notion of a single industry-specific ranking strikes the fleetness/flexibility advocates as an archaically misleading indicator; from a performance point of view, it's not your traditional competitor that matters but who else is in the "arena" with you, engaging and competing for the same customers but often with a different selling orientation.

It is equally wishful thinking to presume that the barriers to entry to biopharmaceuticals remain high enough to discourage would-be competitors attracted by the high margins and market exclusivity conferred by patents. If the industry's traded currency is now not the pill itself but the information that evidences outcomes, which in turn sets the condition for payment, then can it not be said that Google is also a drug company? How do we define our products in an era when a nerve signal generated by an artificial electrical impulse can produce the same physiological and therapeutic effect as a chemical drug?

Posing such basic questions illustrates how fundamentally the competitive set for big Pharma has changed. Finding the correct coordinates for this endless cycle of re-positioning is just as important as a winning scientific hand. Strategy experts like McGrath describe the necessary strategic response as "continuous morphing," and there is no Excel spreadsheet to furnish management with that traditional salve of certainty. All of this draws me to conclude that, assuming the series survives, our Pharma 50 of 2025 will test our current boundaries of comprehension. Yet, I am confident that this is still the one business I can say will help me live to see it.

William Looney, Editor-in-Chief wlooney@advanstar.com Follow Bill on Twitter: @BillPharmExec

Articles in this issue

Surviving the Emerging Market Price Wars: Three Myths & Three Lessons
Surviving the Emerging Market Price Wars: Three Myths & Three Lessons
Adaptive Trial Design: Prepping for Adoption
Adaptive Trial Design: Prepping for Adoption
Promoting Adherence: From Force to Finesse
Promoting Adherence: From Force to Finesse
What Price Innovation?
What Price Innovation?
line-845304-1416904216108.gif
The Urge to Merge
Immunotherapies: The New Hope for Cancer Treatment
Immunotherapies: The New Hope for Cancer Treatment
Pharma 50 Trends: Past, Present, and Future
Pharma 50 Trends: Past, Present, and Future
Pharm Exec's Pharma 50 2014
Pharm Exec's Pharma 50 2014
i3_t-845311-1408522627417.jpg
Compassionate Use Requests Complicate Drug Development
line-845305-1408522654690.gif
Social Media and the In-House Counsel
line-845301-1408522666097.gif
Hopes High as EU Heads Into Leadership Change
Recent Videos
Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.